Survival rates for critically ill Covid patients could be significantly improved and the time they spend in intensive care cut by up to 10 days with the use of existing arthritis drugs, clinical trial results showed on Thursday.
Roche’s Actemra (tocilizumab) and Sanofi’s Kevzara (sarilumab) – both immunosuppressive drugs – slashed the death rates of the sickest Covid patients by 8.5 percentage points, according to the findings, which are yet to be peer-reviewed.
Continue reading https://on.rt.com/ayxx